This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
14


nanotimes


Companies Facts


out by industry and regulators for health reasons. PFOA is a carcinogen, liver toxicant, a developmen- tal toxicant, an immune system toxicant, and also exerts hormonal effects including alteration of thyro- id hormone levels. PFOS is a man-made fluorosurf- actant and global pollutant. PFOS and PFOAs have been found to be persistent, bioaccumulative and toxic to mammalian species. Alexium’s repellency treatment, developed and applied to the Bruck ballistic fabrics, offers excepti- onal performance at a very competitive price, while ensuring a completely PFO and PFOA-free solution. “We look forward to continuing to work with Bruck in order to finalize the commercial relationship and launching value-added and differentiated products. We appreciate the synergy between the two par- ties, the role each partner brings to the table, and the commitment each party is making to push new products into the market”, stated Stefan Susta, COO of Alexium.


Moreover, Alexium International entered the com- mercial roll-out phase of flame retardant, oil/water repellent nylon. The eco-friendly flame retardant treatment is based on a new flame retardant mecha- nism that Alexium has discovered and developed for nylon fabrics. The treatment has met key technical milestones for flame retardancy, water repellency, and durability.


http://www.alexiuminternational.com


output type magnetic sensor for use in automotive equipment, supporting a wide operating temperature


A


LPS ELECTRIC EUROPE has developed the HGPRDT Series high-precision latch 2-phase


range between –40° C to +140° C (-40° F to 284° F), and high voltages up to 30V. Mass production com- menced in January 2012.


http://www.alps.com/products/e/npv_product/120131_ HGPRDT/HGPRDT_E.PDF


for clean, efficient power and energy management, announced notification from NASDAQ that because Altair‘s common stock bid price has fallen below $1.00 from November 21, 2011 to January 5, 2012, Altair is not in compliance with Rule 5550(a)(2), which is NASDAQ‘s minimum bid price rule. The notification has no effect on the listing of Altair‘s common stock at this time, which will continue to trade on the NASDAQ Capital Market under the symbol “ALTI”. The NASDAQ notice states that Altair has been provided a 180-day grace period, through July 5, 2012, to regain compliance with Rule 5550(a) (2). To regain compliance, the bid price for Altair‘s common stock must close at $1.00 or higher for a minimum of 10 consecutive business days within the stated 180-day grace period. At the close of the grace period, if Altair has not regained compliance, it may be eligible for an additional grace period of 180 days, if it meets the initial listing standards, with the exception of bid price, for the NASDAQ Capital Mar- ket and it provides NASDAQ with notice of its intent to timely cure the bid price deficiency.


A http://www.altairnano.com


ltair Nanotechnologies, Inc. (NASDAQ: ALTI), a leading provider of energy storage systems


12-01 :: January 2012


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97